Previous 10 | Next 10 |
2023-03-08 08:46:06 ET Intelligent Bio Solutions ( INBS ) -48% on proposed public offering . Castor Maritime ( CTRM ) -36% . Miromatrix Medical ( MIRO ) -32% on pricing $10M stock offering . United Natural Foods ( UNFI ) -22% on Q2...
2023-03-08 06:00:00 ET 3 Reasons Why Day Trading Penny Stocks is Worth It Investing in penny stocks is a highly speculative and often volatile endeavor. With the potential for high returns and significant losses, it’s important to weigh the pros and cons of day trading penny stoc...
2023-03-07 12:39:41 ET Gainers: ThredUp ( TDUP ) +73% . WW International ( WW ) +49% . Unicycive ( UNCY ) +39% . Protagonist Therapeutics ( PTGX ) +32% . Bionomics ( BNOX ) +28% . Novo Integrated Sciences ( NVOS ) +25% ...
2023-03-07 11:28:43 ET Gainers: Unicycive ( UNCY ) +52% . Bionomics ( BNOX ) +49% . Novo Integrated Sciences ( NVOS ) +37% . Protagonist Therapeutics ( PTGX ) +34% . Allakos ( ALLK ) +22% . Losers: Cara ( CARA ) -28...
(NewsDirect) By Julian Richard, Benzinga Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company spearheading efforts to develop effective, safe, and novel treatments for kidney disease to improve patient and caregiver quality of life due to kidney failure. Its candid...
2023-03-07 06:00:00 ET 3 Penny Stocks Trading Tips for When the Market is Volatile When it comes to trading penny stocks, market uncertainty can be a challenge. But with the right strategies in place, traders can navigate volatile markets and make profitable trades. In this article, we&...
2023-03-06 07:54:24 ET Shares of kidney disease company, Unicycive Therapeutics ( NASDAQ: UNCY ) jump 114% premarket after the Company signed a securities purchase agreement with certain institutional investors that will provide up to $130M in gross proceeds to Unicyci...
$30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and supported by existing investors Nantahala Capital Partners and Rosalind Advisors Inc. Viv...
(NewsDirect) By Julian Richard, Benzinga Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company committed to developing effective and safe treatments for kidney (renal) disease to reduce death rates and improve patients and their caregivers' quality of life by combin...
Data from two abstracts supporting UNI-494’s potential to treat acute and chronic kidney injury accepted for presentation at the 28 th International Conference on Critical Care in Nephrology: the Acute Kidney Injury & CRRT 2023 Conference Highlights key role mitocho...
News, Short Squeeze, Breakout and More Instantly...
Unicycive Therapeutics Inc. Company Name:
UNCY Stock Symbol:
NASDAQ Market:
Unicycive Therapeutics Inc. Website:
LOS ALTOS, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the issuance of U.S. Pate...
LOS ALTOS, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief E...
– Patients preferred OLC more than 4 to 1 over their prior phosphate binder therapy – – Median daily pill burden reduced by half after switch to OLC – LOS ALTOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a...